ARCHIVES

New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

Funding Opportunities.

May 31, 2002

HIPAA Interpretations Vary, Delay Research, ASCO Study Finds

July 31, 2009

ACS Initiates Cage In Approach to Study Of alternative Methods

June 18, 1993

Gleevec First Pediatric Cancer Approval By FDA In 13 Years

May 30, 2003

DCT T Consider Reissuing RFA For Surgical Oncology

March 4, 1983

Smokers May Get Cessation Help From Medicare.

January 14, 2005